» Articles » PMID: 16845708

Damage Accumulation in Systemic Lupus Erythematosus and Its Relation to Disease Activity and Mortality

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2006 Jul 18
PMID 16845708
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To describe damage accrual and the interconnections between disease activity measures, damage accrual, and death in a Nordic lupus cohort.

Methods: Longitudinal study in the population-based Tromso lupus cohort. Disease activity [SLE Disease Activity Index (SLEDAI)] and disease damage [by Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI)] were recorded for each visit. Weighted average SLEDAI scores (WAS) were calculated to correct for variable observation times. Development of damage (SDI > 0), severe damage (SDI >or= 3), and death were used as separate endpoints. Univariate nonparametric analysis identified and hazard ratios (HR) by Cox regression techniques confirmed the independence of predictors for each outcome.

Results: Through 11.9 years of followup, 72 patients (46%) remained free of damage, 51 (32%) developed moderate damage, and 35 (22%) developed severe damage. SDI scores were higher in 37 nonsurvivors (23.4%; SDI 2.1) than in survivors (SDI 0.9; p < 0.05). Damage accrual was linear throughout the first decade of disease. The only independent predictor for SDI >/= 3 was a WAS score > 3 (hazard ratio 2.34; 95% CI 1.1-4.9). Age > 40 years at diagnosis (HR 5.6, 95% CI 2.4-12.7) and WAS > 3 (HR 2.4, 95% CI 1.2-4.9) were significant predictors for death.

Conclusion: Damage accrual in SLE occurred in 54% of patients in a linear fashion over the first decade of disease. Global disease activity was the main determinant of damage accrual. Accrued damage was not an independent risk factor for death, which was predicted by age > 40 years and WAS > 3.

Citing Articles

Trajectories of disease severity and their clinical outcome in real-world patients with systemic lupus erythematosus.

You S, Jang E, Cho S, Sung Y, Jung S Heliyon. 2024; 10(20):e38705.

PMID: 39640596 PMC: 11620140. DOI: 10.1016/j.heliyon.2024.e38705.


Disease activity at the onset of diagnosis as a predictor of disease outcomes in a cohort of patients with systemic lupus erythematosus: A post hoc retrospective analysis of the COMOSLE-EGYPT study.

Mokbel A, Fouad N, Alkemary A, Abdo M Clin Rheumatol. 2024; 44(1):229-235.

PMID: 39548046 PMC: 11729062. DOI: 10.1007/s10067-024-07222-w.


Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Altabas-Gonzalez I, Rua-Figueroa I, Mourino C, Roberts K, Jimenez N, Martinez-Barrio J Lupus Sci Med. 2024; 11(2.

PMID: 39097409 PMC: 11331961. DOI: 10.1136/lupus-2023-001064.


Epidemiology of systemic lupus erythematosus in Korea.

Han J, Cho S, Sung Y J Rheum Dis. 2023; 30(4):211-219.

PMID: 37736591 PMC: 10509641. DOI: 10.4078/jrd.2023.0037.


The BILAG-2004 index is associated with development of new damage in SLE.

Yee C, Gordon C, Akil M, Lanyon P, Edwards C, Isenberg D Rheumatology (Oxford). 2022; 62(2):668-675.

PMID: 35686924 PMC: 9891406. DOI: 10.1093/rheumatology/keac334.